Molecular Diagnostics News and Research

RSS

Helicos BioSciences to focus business on diagnostics markets

Helicos BioSciences Corporation announced today that, as part of the Company's previously disclosed efforts to consider alternatives to its existing long-term strategy, it is in the process of implementing a strategic shift to focus the business on the diagnostics markets. In connection with this effort, the Company has committed to a consolidation and reorganization of its operations in order to reduce operating costs.

18 May 2010

Caliper to sell RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5M

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.

18 May 2010

GE Healthymagination Fund invests $5M in CardioDx

GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

14 May 2010

LifeCodexx AG develops test using Next Generation Sequencing technologies for prenatal diagnostics

LifeCodexx AG has started operational research and development work on clinically validated diagnostic tests by using Next Generation Sequencing technologies. The work currently focuses on the field of prenatal diagnostics.

12 May 2010

Prenatal screening, genetic counseling essential for preventing alpha-thalassemia: Researchers

Researchers from Mahidol University have developed a rapid, high-throughput screening method for prevention and control of thalassemia. The related report by Munkongdee et al, "Rapid diagnosis of α-thalassemia by melting curve analysis," appears in the May 2010 issue of The Journal of Molecular Diagnostics.

12 May 2010

Nanosphere reports $0.8 million revenue for first-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Caliper Life Sciences, Inc., today reported its first quarter 2010 results.

29 Apr 2010

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

RedPath Integrated Pathology, Inc., a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has entered into a binding agreement to be acquired by ExonHit Therapeutics, S.A., a leading French diagnostics and therapeutics biotech company for an upfront payment of $12.5M in cash and $10M in stock, and starting in 2012, subsequent additional payment up to $9.5M dependent on the achievement of sales targets.

27 Apr 2010

New blood test to determine patients at low risk for rejection of transplanted hearts

After his heart transplant in 2005, Ramon Llenado underwent a biopsy every week, then every month, then every three months. Most heart transplant patients face a lifetime of these invasive tests, which involve snipping out tiny pieces of heart to check for possible organ rejection.

23 Apr 2010

Enigma ML instrument system to be showcased at InnovHealth 2010 summit

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it will be a product provider at the InnovHealth - Middle East Healthcare Innovations Summit in Abu Dhabi on 25 and 26 April 2010 and will be presenting the Enigma ("Mini Laboratory") instrument system.

22 Apr 2010

Rheonix announces completion of $12.6 million Series A financing

Rheonix, Inc. today announced the completion of a $12.6 million Series A financing to continue development of the Rheonix CARD™ (Chemistry And Reagent Device) system. This powerful, analytic platform for the life-science industry vertically integrates all the functions of traditional molecular diagnostic instrumentation into a single system to achieve unprecedented raw sample preparation, molecular amplification and multiplex analysis.

21 Apr 2010

MDx to better health care, cut costs and make personalized medicine a worldwide reality

The rapidly growing field of molecular diagnostics is addressing critical unmet needs in healthcare by enabling early disease detection and better disease segmentation, and by predicting relapse and response to therapy, according to a global industry review released today by Scientia Advisors.

20 Apr 2010

Investment report on Sequenom from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sequenom Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

20 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

Enigma Diagnostics receives patent for amplification consumables

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments.

19 Apr 2010

IMAGE trial results to be presented at International Society for Heart & Lung Transplantation meeting

XDx, Inc., a molecular diagnostics company focused on noninvasive tests for the monitoring of immune-mediated conditions, today announced that results from its Invasive Monitoring Attenuation through Gene Expression trial will be presented by Dr. Michael X. Pham, Stanford University Medical Center, during a plenary session at the International Society for Heart & Lung Transplantation 30th Anniversary Meeting & Scientific Sessions in Chicago this month.

17 Apr 2010

UDH to participate in Abbott's new PLEX-ID BPEP

Abbott today announced that the Utah Department of Health is one of five sites in the United States to participate in Abbott's new PLEX-ID Biopreparedness Evaluation Program, which involves Abbott, the Association of Public Health Laboratories and five state public health labs.

16 Apr 2010

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.

15 Apr 2010